The 3xTG-AD mouse model is a triple transgenic mouse model of Alzheimer's disease that expresses three mutant genes associated with familial AD: APP Swedish (KM670/671NL), MAPT P301L, and PSEN1 M146V. Developed by Oddo et al. in 2003, this model is unique in that it develops both amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs), making it the most comprehensive mouse model for studying AD pathogenesis and the interaction between the two hallmark pathologiesoddo2003.
The 3xTG-AD model has become one of the most widely used animal models for AD research due to its ability to reproduce both major pathological hallmarks of the disease in a temporal pattern that roughly mirrors human disease progression.
The 3xTG-AD model contains three human transgenes driven by neuron-specific promotersoddo2003:
| Gene | Mutation | Promoter | Effect |
|---|---|---|---|
| APP | Swedish (KM670/671NL) | Thy1.2 | Increased Aβ production |
| MAPT (Tau) | P301L | Thy1.2 | Tau aggregation |
| PSEN1 | M146V | Endogenous (knock-in) | Altered γ-secretase |
The Swedish double mutation (K670N/M671L) in the APP gene was originally identified in a Swedish family with early-onset familial AD. This mutation is located at the β-secretase cleavage site and increases amyloid-beta production by 3-4 fold, particularly increasing the more aggregation-prone Aβ₁₋₄₂ speciesoddo2003.
The P301L tau mutation in MAPT is associated with frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17). This mutation promotes hyperphosphorylation and aggregation of tau into neurofibrillary tangles by reducing microtubule binding affinity. In the 3xTG-AD model, tau pathology develops progressively with age, first appearing in the hippocampus and then spreading to cortical regionsoddo2004.
The M146V presenilin-1 mutation in PSEN1 is a familial AD mutation that enhances γ-secretase activity, leading to increased Aβ₁₋₄₂ production. The mutation is knocked into the endogenous mouse Psen1 locus, ensuring physiologically appropriate expression levelslaferla2012.
| Feature | Details |
|---|---|
| Promoter | Thy1.2 (neuron-specific) |
| Expression | Neuronal, CNS-specific |
| Transgenes | APP Swedish, MAPT P301L, PSEN1 M146V |
| Tissue | Brain (central nervous system) |
The amyloid pathology in 3xTG-AD mice follows a defined temporal progression. At 6 months, diffuse Aβ deposits appear in the subiculum and cortex. By 12 months, plaque density increases significantly throughout the hippocampus and cortexoddo2004.
Tau pathology develops after Aβ pathology, consistent with the amyloid cascade hypothesis. The P301L mutation promotes aggregation, but true neurofibrillary tangles are limited by species differences in tau sequencehansson2019.
Synaptic dysfunction is one of the earliest measurable deficits in the 3xTG-AD model. Electrophysiological studies reveal impaired LTP in the hippocampal CA1 region as early as 3-4 months, before the appearance of Aβ plaques or tau tanglessingh2015.
| Age | Pathology | Behavior |
|---|---|---|
| 2-4 months | Minimal | Normal |
| 4-6 months | Early Aβ aggregation | Subtle synaptic deficits |
| 6-12 months | Plaque formation, early tau | Cognitive impairment |
| 12-18 months | Dual pathology (plaques + tangles) | Severe cognitive decline |
| >18 months | Full neurodegeneration | Marked AD phenotype |
The 3xTG-AD model exhibits robust neuroinflammation, with microglial activation accompanying Aβ and tau pathology. Activated microglia cluster around Aβ plaques, adopting a disease-associated microglia (DAM) phenotypele2014.
Microglial activation can be detected using Iba1 immunohistochemistry, with increased staining density around plaques and in regions of tau pathology.
Reactive astrocytes are also prominent in the 3xTG-AD model. GFAP-positive astrocytes show hypertrophy and increased proliferation in response to neuropathologyrodriguez2013.
| Advantage | Description |
|---|---|
| Dual pathology | Both Aβ and tau pathology in one model |
| Age-dependent progression | Clear temporal progression of pathologies |
| Behavioral deficits | Reproducible cognitive impairment |
| Synaptic pathology | Early synaptic dysfunction before plaques/tangles |
| Cross-seeding studies | Unique ability to study Aβ-tau interactions |
| Limitation | Description |
|---|---|
| Strain variability | Genetic background affects phenotype |
| Non-physiological expression | Thy1.2 promoter drives higher than normal levels |
| Translation concerns | Murine model cannot fully replicate human AD |
| Tau pathology | Less robust neurofibrillary tangles than in human AD |
| Species differences | Mouse tau does not form true human-style NFTs |
The 3xTG-AD model is widely used to testlaferla2012:
Studies using the 3xTG-AD model have demonstrated that Aβ pathology can accelerate tau propagation, supporting the hypothesis that Aβ drives downstream tau pathologypooler2012.
| Feature | 3xTG-AD | APP/PS1 | 5xFAD | Tg2576 |
|---|---|---|---|---|
| Amyloid plaques | Yes | Yes | Yes | Yes |
| Neurofibrillary tangles | Yes | No | Minimal | No |
| Tau pathology | Yes | No | No | No |
| Onset (plaques) | 6 months | 6-9 months | 2 months | 9-12 months |
| Dual pathology | Yes | No | No | No |
| Cost | High | Medium | Medium | Medium |